🔗 Share this article

While America undertakes historic revisions to its immunization schedules, one figure has surfaced in a surprising turn: Tracy Beth Høeg, an American of Danish descent physician and public health researcher who initially gained attention by casting doubt on COVID-19 shots during the global health crisis and has zeroed in on alleged deaths following COVID-19 immunization in her recent position at the Food and Drug Administration.

Planned Changes to Pediatric Immunization Program

Health officials were set to announce sweeping changes to the pediatric vaccine schedule earlier this month, bringing the US with the Danish immunization schedule, it is understood – a major change that would place the US out of step with a large portion of the international standard with no evidence for public health gain. The planned update has been delayed until the new year.

In place of Vinay Prasad, Tracy Beth Høeg is set to speak at the event. She was recently named acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to lead the center this year.

A Shift at the Agency

The acting appointment could signify a closer partnership between the pharmaceutical and vaccine centers as Høeg and Dr. Prasad consolidate power at the regulatory agency – and it points to a renewed priority upon reevaluating long-standing immunizations at the FDA.

Dr. Høeg has frequently advocated for ending certain childhood shot schedules in the US so as to align more similar to the Danish model, a country with universal health coverage and a population roughly the size of the state of Wisconsin.

To date public appearances, she has persisted in emphasizing on vaccination policy – traditionally the responsibility of Dr. Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of drug regulation.

Questions Over Expertise

Høeg has no obvious background in medication creation, regulation or administrative roles, which has been standard for previous leaders of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a senior adviser to the FDA chief and the vaccine center since earlier this year.

“She doesn’t seem to have the necessary background” for leading the CDER, remarked a neurologist and psychiatrist. “She’s never run a clinical trial. She has no expertise in running a sizeable institution. She has no expertise in pharmaceutical oversight.”

Previous directors of the center would “be deeply familiar with legal statutes and the science of pharmaceutical innovation”, commented Dr. Janet Woodcock. “Objectively, she has not acquired the sort of resume that prior appointees who led the center have had.”

The drug center has an immense workload at the FDA, the former commissioner emphasized.

“Everybody just pays attention on the new drug program, but the generic drug division clears thousands of generic medications. There is also a biologic copycat branch, OTC medication office and other areas, and every single one need to be looked after,” Woodcock explained. “The thing you overlook, that’s the thing that I always told people is going to come back to haunt you.”

Furthermore, a substantial administrative aspect to the job, which supervises in excess of 5,000 employees. “It’s a massive administrative position, if you execute it properly,” the former official added.

Agency Reaction and Controversial Policies

When asked about inquiries about Høeg’s credentials and whether this selection indicates more teamwork among FDA leaders on immunizations, a spokesperson stated that the “concerns rely on incorrect premises”.

“Her resume is consistent with the duties of her job,” the official explained, noting the period Høeg spent counseling the FDA commissioner on “drug safety and approval science, including computerized risk analysis and vaccine surveillance”.

As the temporary head, Høeg inherits the commissioner’s controversial fast-track approval initiative, a contentious expedited medication authorization process that reportedly concerned her preceding directors. “How are these drugs being picked for this expedited pathway? Who takes the decisions?” Howard questioned. “There is a lot of secrecy happening at the agency right now.”

In general, he stated, “the agency appears to be shifting towards less stringent oversight of most medications, aside from vaccines.”

Established History on Vaccines

With immunizations, Høeg has a more documented, if troubling, track record, Howard have noted. She published a research paper using non-validated public submissions to determine the incidence of myocarditis following COVID-19 immunization. She counseled the state of Florida chief medical officer Dr. Joseph Ladapo, who allegedly have modified findings to indicate Covid vaccinations are riskier than they are.

Among her “wish list” for the incoming government featured revising rules for new vaccines and ending “non-essential” immunizations, she said following the vote on a audio program. At the agency, Dr. Høeg has allegedly floated the idea of excluding adolescent males from receiving COVID-19 vaccinations.

“She’s an thorough true believer who begins with her conclusions and works backwards to accommodate the evidence in a very disingenuous, fraudulent manner,” Howard argued.

Taking Control and a “Campaign of Retribution”

Dr. Høeg became part of other skeptics, {like|